Nurix Therapeutics Reports Widened Net Loss, Decreased Collaboration Revenue, and Expanded ATM Program

summarizeSummary

Nurix Therapeutics' first quarter 2026 financial results indicate a significant increase in net loss and a substantial decline in collaboration revenue. The net loss widened to $87.2 million from $56.4 million year-over-year, primarily due to a $12.2 million decrease in collaboration revenue as certain Sanofi agreement terms concluded. Research and development expenses increased by $14.5 million, reflecting accelerated clinical trial enrollment for lead candidates. To bolster its financial position and support long-term plans, the company expanded its "at the market" equity offering program, authorizing the potential sale of an additional $300 million in common stock. While the company reports a cash runway of at least 12 months, the increased cash burn and reliance on equity financing signal potential future dilution for shareholders.

check_boxKey Events

• Q1 Net Loss Widens

  Net loss increased to $87.2 million for the three months ended February 28, 2026, compared to $56.4 million for the same period last year.

• Collaboration Revenue Declines Significantly

  Total collaboration revenue decreased by $12.2 million to $6.25 million, primarily due to the conclusion of certain Sanofi collaboration terms.

• R&D Expenses Increase

  Research and development expenses rose by $14.5 million to $84.1 million, driven by accelerated clinical trial enrollment and increased contract research costs.

• ATM Program Expanded

  The company amended its "at the market" equity distribution agreement on March 6, 2026, authorizing the potential sale of an additional $300 million in common stock.

auto_awesomeAnalysis

Nurix Therapeutics' first quarter 2026 financial results indicate a significant increase in net loss and a substantial decline in collaboration revenue. The net loss widened to $87.2 million from $56.4 million year-over-year, primarily due to a $12.2 million decrease in collaboration revenue as certain Sanofi agreement terms concluded. Research and development expenses increased by $14.5 million, reflecting accelerated clinical trial enrollment for lead candidates. To bolster its financial position and support long-term plans, the company expanded its "at the market" equity offering program, authorizing the potential sale of an additional $300 million in common stock. While the company reports a cash runway of at least 12 months, the increased cash burn and reliance on equity financing signal potential future dilution for shareholders.